Inflammatory Bowel Diseases最新文献

筛选
英文 中文
Bowel urgency, ulcerative colitis, and the importance of being earnest. 肠急症,溃疡性结肠炎,以及认真的重要性。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-14 DOI: 10.1093/ibd/izag245
Jimmy K Limdi
{"title":"Bowel urgency, ulcerative colitis, and the importance of being earnest.","authors":"Jimmy K Limdi","doi":"10.1093/ibd/izag245","DOIUrl":"https://doi.org/10.1093/ibd/izag245","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial. 在一项随机安慰剂对照试验中,微生物群移植治疗可改善溃疡性结肠炎症状,而不依赖于供体移植。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-14 DOI: 10.1093/ibd/izag236
Daphne Moutsoglou, William A Nickols, Dina C Belhasan, Levi Teigen, Sharon Lopez, Lulu Chen, Amanda J Kabage, Monika Fischer, Christopher Staley, Alexander Khoruts, Byron P Vaughn
{"title":"Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial.","authors":"Daphne Moutsoglou, William A Nickols, Dina C Belhasan, Levi Teigen, Sharon Lopez, Lulu Chen, Amanda J Kabage, Monika Fischer, Christopher Staley, Alexander Khoruts, Byron P Vaughn","doi":"10.1093/ibd/izag236","DOIUrl":"https://doi.org/10.1093/ibd/izag236","url":null,"abstract":"<p><strong>Background: </strong>Several clinical trials have assessed microbiota transplant therapy (MTT) in ulcerative colitis (UC); however, none have assessed a standardized MTT product. We developed a standardized, oral, lyophilized MTT product and previously reported the primary endpoint of engraftment at week 12. Here, we assessed clinical outcomes and the association with donor engraftment.</p><p><strong>Methods: </strong>A single-center, randomized, double-blind, placebo-controlled pilot trial of patients with UC with an endoscopic Mayo score ≥1, who received MTT or placebo for 8 weeks. Symptom and fecal assessments occurred at baseline and weeks 4, 8, and 12. Secondary outcomes included the partial Mayo score (pMS) and correlation to donor engraftment. Stool microbiota were assessed via 16S rRNA sequencing and donor engraftment measured using SourceTracker.</p><p><strong>Results: </strong>Participants receiving MTT (n = 13) had significantly higher donor engraftment at all measured time points compared with placebo (n = 14). Compared with baseline symptoms, participants who received MTT had significantly lower pMS at weeks 4 and 8, while no significant changes in pMS were noted in those randomized to placebo. There was no correlation between donor engraftment and pMS or clinical response. There was no significant pattern in engrafting donor taxa in those that met the threshold of clinical response at week 4 vs participants that did not meet clinical response.</p><p><strong>Conclusions: </strong>Daily dosing of encapsulated MTT for 8 weeks reduces symptoms of UC as measured by the pMS. However, donor engraftment did not correlate to pMS or clinical responses.NCT03948919, Fecal Transplant for Ulcerative Colitis, https://clinicaltrials.gov/study/NCT03948919.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study. 生物暴露急性严重溃疡性结肠炎的环孢素-生物桥接:一项单中心回顾性队列研究
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-13 DOI: 10.1093/ibd/izag222
Alexandre Nuzzo, Marc Harb, Carmen Stefanescu, Teodor Berea, Yoram Bouhnik, Xavier Treton, Lara Ribeiro, Francisca Joly, Thomas Bazin
{"title":"Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.","authors":"Alexandre Nuzzo, Marc Harb, Carmen Stefanescu, Teodor Berea, Yoram Bouhnik, Xavier Treton, Lara Ribeiro, Francisca Joly, Thomas Bazin","doi":"10.1093/ibd/izag222","DOIUrl":"https://doi.org/10.1093/ibd/izag222","url":null,"abstract":"<p><strong>Background: </strong>In corticosteroid-resistant acute severe ulcerative colitis (ASUC), cyclosporine is frequently used in biologic-exposed patients, but data on maintenance strategies after cyclosporine response remain limited. We aimed to describe 12-month outcomes after a cyclosporine-to-biologic bridge and to explore outcomes according to maintenance therapy.</p><p><strong>Methods: </strong>This single-center retrospective study screened all patients treated with cyclosporine for ASUC between 2014 and 2024. Patients who responded to cyclosporine and subsequently received vedolizumab or ustekinumab as maintenance therapy were included. The primary endpoint was 12-month colectomy-free survival. Secondary endpoints included steroid-free clinical remission, combined clinical/biological remission, treatment persistence, and adverse events. Comparisons between maintenance therapies were exploratory.</p><p><strong>Results: </strong>Among 67 patients treated with cyclosporine for ASUC, 44 responders were included (35 vedolizumab, 9 ustekinumab, and 96% biologic-exposed). Median follow-up was 39 months. Maintenance therapy was initiated a median of 7 days after cyclosporine initiation. Overall 12-month colectomy-free survival was 73% (95% CI, 61-88). In exploratory analyses, colectomy-free survival appeared lower with ustekinumab than with vedolizumab (47% vs 79%, log-rank P = .03). At 12 months, overall treatment persistence was 46% and combined clinical/biological remission was 34%. Adverse events were predominantly renal or neurological.</p><p><strong>Conclusions: </strong>In this predominantly biologic-exposed, cyclosporine-responsive ASUC cohort, a bridge to vedolizumab or ustekinumab was associated with 73% colectomy-free survival at 12 months and an acceptable safety profile. Comparisons between maintenance therapies remain exploratory.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Readability and quality of online information on GLP-1 receptor agonists in inflammatory bowel disease. 炎性肠病中GLP-1受体激动剂在线信息的可读性和质量。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-13 DOI: 10.1093/ibd/izag239
Sudharshan Raajkumar Ezhil, Omair Khokhar, Abdelrhman Refaey, Pavan Vemulakonda, Urwah Ahmad, Marie Borum
{"title":"Readability and quality of online information on GLP-1 receptor agonists in inflammatory bowel disease.","authors":"Sudharshan Raajkumar Ezhil, Omair Khokhar, Abdelrhman Refaey, Pavan Vemulakonda, Urwah Ahmad, Marie Borum","doi":"10.1093/ibd/izag239","DOIUrl":"https://doi.org/10.1093/ibd/izag239","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extending health equity in IBD to incarcerated populations. 将IBD的卫生公平扩大到监禁人群。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-13 DOI: 10.1093/ibd/izag249
Jessica L Sheehan
{"title":"Extending health equity in IBD to incarcerated populations.","authors":"Jessica L Sheehan","doi":"10.1093/ibd/izag249","DOIUrl":"https://doi.org/10.1093/ibd/izag249","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic factors and outcomes in upper gastrointestinal Crohn's disease: A scoping review. 上消化道克罗恩病的预后因素和预后:一项范围综述
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-12 DOI: 10.1093/ibd/izag200
Reyad Elzaanoun, Navneet Natt, Daniel Lupas, Yuhong Yuan, Rokhsana Mortuza, Sudheer Vuyyuru, Mohammed Shehab, Christopher Ma, Silvio Danese, Laurent Peyrin-Biroulet, Siddharth Singh, Vipul Jairath, Rocio Sedano
{"title":"Prognostic factors and outcomes in upper gastrointestinal Crohn's disease: A scoping review.","authors":"Reyad Elzaanoun, Navneet Natt, Daniel Lupas, Yuhong Yuan, Rokhsana Mortuza, Sudheer Vuyyuru, Mohammed Shehab, Christopher Ma, Silvio Danese, Laurent Peyrin-Biroulet, Siddharth Singh, Vipul Jairath, Rocio Sedano","doi":"10.1093/ibd/izag200","DOIUrl":"https://doi.org/10.1093/ibd/izag200","url":null,"abstract":"<p><strong>Background: </strong>Upper gastrointestinal (UGI) involvement occurs in about 13% of patients with Crohn's disease (CD) and is variably defined across guidelines, which complicates prognosis. We mapped adult data on prognostic factors and outcomes in UGI‑CD and identified evidence gaps.</p><p><strong>Methods: </strong>A comprehensive search strategy was applied to MEDLINE, Embase, and Cochrane Central through November 26, 2025. We included studies reporting prognostic factors in patients with UGI-CD. We synthesized evidence across 3 domains: (1) patient and disease characteristics associated with UGI involvement at diagnosis, (2) the comparative prognosis of UGI-CD vs non-UGI disease, and (3) among patients with UGI-CD, factors associated with long-term adverse outcomes. Findings were synthesized narratively.</p><p><strong>Results: </strong>From 3297 screened records, 732 underwent full text assessment, and 43 primary studies were included. A total of 101 prognostic factor-outcome relationships were identified. In domain 1 (patient and disease characteristics associated with UGI involvement at diagnosis), younger age at onset was the most consistently reported factor associated with UGI involvement. In domain 2 (comparative prognosis vs non-UGI disease), studies evaluating pooled L4 disease frequently associated UGI involvement at diagnosis with higher surgical risk, incident stricture development, and adverse long-term outcomes. However, studies that distinguished anatomic subtypes suggested that risk is not uniform: jejunal/proximal small bowel disease generally followed a more aggressive course, whereas esophagogastroduodenal-limited disease appeared to have a comparatively more favorable prognosis. In domain 3 (among patients with UGI-CD, factors associated with long-term adverse outcomes), a higher Simple Endoscopic Score for Crohn's Disease was associated with subsequent surgery in a duodenal stricture cohort on univariable analysis; an independent prognostic effect was not established.</p><p><strong>Conclusions: </strong>The available literature suggests that prognosis in UGI-CD is not uniform. Jejunal/proximal small bowel disease appears to follow a more aggressive course than esophagogastroduodenal-limited disease, although interpretation is limited by predominantly retrospective designs, heterogeneous definitions, and inconsistent adjustment for confounders.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of in vitro fertilization on disease activity and pregnancy outcomes in women with inflammatory bowel disease. 体外受精对炎症性肠病患者疾病活动性和妊娠结局的影响
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-10 DOI: 10.1093/ibd/izag223
Rohit Khanna, Nicole M Garcia, Cynthia Fenton, Millie Long, Uma Mahadevan
{"title":"Impact of in vitro fertilization on disease activity and pregnancy outcomes in women with inflammatory bowel disease.","authors":"Rohit Khanna, Nicole M Garcia, Cynthia Fenton, Millie Long, Uma Mahadevan","doi":"10.1093/ibd/izag223","DOIUrl":"https://doi.org/10.1093/ibd/izag223","url":null,"abstract":"<p><strong>Background: </strong>Women with inflammatory bowel disease (IBD) increasingly utilize assisted reproductive technologies (ARTs) like in vitro fertilization and oocyte cryopreservation. Data regarding ART associated IBD flare risk are limited. We evaluated the risk of disease exacerbation among women with IBD undergoing ART.</p><p><strong>Methods: </strong>This retrospective single-center study evaluated women with IBD undergoing ART. Electronic medical records were abstracted for demographics, IBD history, and fertility history. Disease activity was assessed via medication exposure, biomarkers, and healthcare utilization 6 months pre- and post-ART. The primary outcome was disease flare (therapy modification, steroid initiation, or IBD-related hospitalization) within 6 months of ART. Secondary outcomes included successful egg retrieval, biochemical pregnancy, and live birth. Demographics were analyzed at the patient level and outcome data at the ART encounter level.</p><p><strong>Results: </strong>We included 49 women (mean age 37.1 ± 4.01 years, body mass index 25.7 ± 4.72 kg/m2) who underwent 149 ART encounters. Most had Crohn's disease (63.3%) or ulcerative colitis (34.7%), with a mean disease duration of 13.4 ± 7.16 years. Pre-ART, therapies included ustekinumab (20.8%), anti-tumor necrosis factors (12.1%), and corticosteroids (6.7%), or no therapy (29.5%). In 149 ART encounters (86 oocyte retrievals and 63 embryo transfers), the overall disease flare rate was 3.4% (n = 5 of 149, representing 5 unique patients). Flares occurred after embryo transfer during established pregnancy (gestational week ≥8), with no flares occurring during or immediately following oocyte retrieval. Secondary endpoints showed low rates of new corticosteroid use (2.7%), IBD-related hospitalizations (0.7%), and medication dose escalation (0.7%). Among the 63 embryo transfers, biochemical pregnancy occurred in 63.5% (n = 40 of 63) and live births in 42.9% (n = 27 of 63).</p><p><strong>Conclusions: </strong>Across all 149 ART encounters, patients with IBD demonstrated low flare risk and live birth rates comparable to the general population. Under multidisciplinary guidance, ART is a safe and viable option in IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cellular therapies and immune reprogramming in inflammatory bowel disease: lessons learned and the promise of CAR T-cell therapy. 炎症性肠病的细胞疗法和免疫重编程:CAR - t细胞疗法的经验教训和前景
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-10 DOI: 10.1093/ibd/izag233
Tommaso L Parigi, Bianca N Islam, Theresa T Pizarro, Fabio Cominelli
{"title":"Cellular therapies and immune reprogramming in inflammatory bowel disease: lessons learned and the promise of CAR T-cell therapy.","authors":"Tommaso L Parigi, Bianca N Islam, Theresa T Pizarro, Fabio Cominelli","doi":"10.1093/ibd/izag233","DOIUrl":"https://doi.org/10.1093/ibd/izag233","url":null,"abstract":"<p><p>Despite major therapeutic advances, inflammatory bowel disease (IBD) remains incurable, and many patients experience primary non-response, secondary loss of response, progressive bowel damage, or lifelong dependence on immunomodulatory therapy. Cellular immunotherapies offer the possibility of moving beyond chronic immune suppression toward durable immune reprogramming. Earlier approaches in IBD, including hematopoietic stem cell transplantation, mesenchymal stem cells, and regulatory T-cell-based therapies, have provided important proof-of-concept but have been limited by toxicity, inconsistent efficacy, local rather than systemic effects, or unresolved manufacturing and durability challenges. Chimeric antigen receptor (CAR) T-cell therapy represents the next-generation strategy that combines potent immune remodeling with antigen-specific targeting. Initially developed for hematological malignancies, CAR T cells have recently shown striking efficacy in refractory autoimmune diseases, particularly through CD19-mediated depletion of B-lineage cells and induction of drug-free remission. In ulcerative colitis, renewed interest in B cells has been driven by evidence of plasmablast expansion, IgG-skewed humoral responses, anti-integrin αvβ6 autoantibodies, and the limitations of conventional anti-CD20 depletion. The first reported case of multidrug-resistant ulcerative colitis treated with CD19 CAR T cells demonstrated rapid clinical, biochemical, endoscopic, and histological remission, providing proof-of-concept for deep B-cell targeting in IBD. However, major uncertainties remain, including long-term durability, relapse after B-cell reconstitution, safety, cost, feasibility, and the risk of CAR T-associated gastrointestinal toxicity. Prospective trials with mechanistic mucosal monitoring are now needed to define the therapeutic potential and appropriate positioning of CAR-based strategies in IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study. 英夫利昔单抗和托法替尼治疗溃疡性结肠炎的比较疗效:一项多中心现实世界研究
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-10 DOI: 10.1093/ibd/izag248
Noboru Mizuta, Naohiko Kinoshita, Kazuki Kakimoto, Azusa Hara, Hiroaki Ito, Hitoshi Hongo, Kei Moriya, Keijiro Numa, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Takako Miyazaki, Shiro Nakamura, Hiroki Nishikawa
{"title":"Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study.","authors":"Noboru Mizuta, Naohiko Kinoshita, Kazuki Kakimoto, Azusa Hara, Hiroaki Ito, Hitoshi Hongo, Kei Moriya, Keijiro Numa, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Takako Miyazaki, Shiro Nakamura, Hiroki Nishikawa","doi":"10.1093/ibd/izag248","DOIUrl":"https://doi.org/10.1093/ibd/izag248","url":null,"abstract":"<p><strong>Background: </strong>and Aim: Infliximab (IFX) and tofacitinib (TOF) are advanced therapies for ulcerative colitis (UC), but real-world comparative data by prior advanced therapy (AT) exposure remain limited. We compared effectiveness by prior AT exposure.</p><p><strong>Methods: </strong>This multicenter retrospective cohort study included adults with UC who initiated IFX or TOF between June 2010 and May 2025. The primary analysis was restricted to May 2018 onward, when both were available in Japan. AT-naive and AT-exposed cohorts were analyzed separately using overlap weighting. The primary outcome was corticosteroid-free clinical remission at week 52.</p><p><strong>Results: </strong>Of 266 patients (137 IFX, 129 TOF), the primary analysis included 76 AT-naive (27 IFX, 49 TOF) and 120 AT-exposed (40 IFX, 80 TOF) patients. Week 14 remission did not differ significantly between treatments in either cohort. At week 52, remission numerically favored TOF in AT-naive patients (IFX, 43.9%; TOF, 64.5%; odds ratio [OR], 2.32; 95% CI, 0.84-6.44; P = .105), whereas remission was higher with TOF in the AT-exposed cohort (IFX, 19.0%; TOF, 38.8%; OR, 2.71; 95% CI, 1.08-6.80; nominal P = .034). Three-year treatment persistence did not differ significantly in either cohort but numerically favored TOF in AT-naive patients (IFX, 39.2%; TOF, 61.5%; hazard ratio, 0.64; 95% CI, 0.31-1.36). Multiple-imputation analyses yielded similar findings.</p><p><strong>Conclusions: </strong>Week 52 remission numerically favored TOF in AT-naive patients and was higher with TOF in AT-exposed patients. Clinically relevant differences in 3-year persistence could not be ruled out, particularly in AT-naive patients. These findings are exploratory.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr virus and inflammatory bowel disease: a systematic review of its clinical significance and potential pathogenic role. eb病毒与炎症性肠病:其临床意义和潜在致病作用的系统综述。
IF 5.5 3区 医学
Inflammatory Bowel Diseases Pub Date : 2026-11-10 DOI: 10.1093/ibd/izag230
Maria Manuela Estevinho, Hyder Said, Anubhab Nandy, Scott B Snapper, Jean-Frederic Colombel, Manasi Agrawal
{"title":"Epstein-Barr virus and inflammatory bowel disease: a systematic review of its clinical significance and potential pathogenic role.","authors":"Maria Manuela Estevinho, Hyder Said, Anubhab Nandy, Scott B Snapper, Jean-Frederic Colombel, Manasi Agrawal","doi":"10.1093/ibd/izag230","DOIUrl":"https://doi.org/10.1093/ibd/izag230","url":null,"abstract":"<p><strong>Background: </strong>Several studies report an association between Epstein-Barr virus (EBV) and inflammatory bowel disease (IBD). This review critically synthesizes current evidence on these association between EBV and IBD, its potential mechanisms, clinical implications, and research gaps.</p><p><strong>Methods: </strong>A systematic search identified studies investigating EBV in IBD using serological, molecular, and tissue-based approaches. Data on EBV prevalence, viral load, disease phenotype, treatment status, and clinical outcomes were extracted, and study quality was assessed. A narrative review examined proposed mechanisms that may potentially link EBV to intestinal inflammation.</p><p><strong>Results: </strong>From 7271 citations, 45 studies met inclusion criteria. EBV was more frequently detected in intestinal tissue from IBD patients than in controls, particularly in active or refractory disease, whereas findings for seroprevalence and blood-based markers were less consistent. Some longitudinal studies reported associations between prior EBV exposure and subsequent IBD, particularly Crohn's disease, but these observations do not establish a causal relationship. Proposed mechanisms involving EBV-infected B cells, molecular mimicry, and altered cytokine signaling provide biological plausibility but remain unproven in IBD. EBV latency programs and age at seroconversion may influence disease progression and reactivation risk, although data remain limited. Corticosteroids and therapy with infliximab plus azathioprine have been associated with higher EBV loads, especially in refractory disease, yet these findings may be confounded by disease severity and treatment exposure.</p><p><strong>Conclusions: </strong>Current evidence supports an association between EBV and IBD, particularly in severe and refractory disease but does not establish-and equally does not exclude-a pathogenic role for EBV. Considerable methodological heterogeneity in study design and EBV detection methods and the observational nature of the available data limit causal interpretation. Prospective mechanistic studies are needed to determine whether EBV is a causal contributor, a disease modifier, or a marker of underlying immune dysregulation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书